

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 May 2019

Cumulative for April and May 2019



Contents

Summary of decisions effective 1 May 2019	3
Section H changes to Part II	5
Index	14

Summary of decisions

EFFECTIVE 1 MAY 2019

- Bupivacaine hydrochloride with adrenaline (Marcain with Adrenaline) inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial and inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – price decrease and addition of HSS
- Chlorhexidine with cetrimide irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle – new listing
- Compound hydroxybenzoate (Midwest) soln – new listing
- Doxycycline (Doxine) tab 100 mg, 500 tab pack – new listing
- Doxycycline (Doxine) tab 100 mg, 250 tab pack – to be delisted 1 November 2019
- Eftrenonacog alfa [recombinant factor IX] (Alprolix) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vial – new listing
- Eptacog alfa [recombinant factor VIIA] (NovoSeven RT) inj 1 mg, 2 mg, 5 mg and 8 mg syringe – amended restriction criteria
- Ertapenem (Invanz) inj 1 g vial – price decrease and addition of HSS
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 U, 1,000 U and 2,500 U – price decrease and amended restriction criteria
- Flumazenil (Hameln) inj 0.1 mg per ml, 5 ml ampoule, 10 inj pack – new listing
- Flumazenil (Hameln) inj 0.1 mg per ml, 5 ml ampoule, 5 inj pack – to be delisted from 1 August 2019
- Lamotrigine (Logem) tab dispersible 25 mg, 50 mg and 100 mg – price decrease and addition of HSS
- Lamotrigine (Arrow-Lamotrigine and Lamictal) tab dispersible 25 mg, 50 mg and 100 mg – to be delisted from 1 October 2019
- Levetiracetam (Everet) tab 250 mg, 500 mg, 750 mg and 1,000 mg – price decrease and addition of HSS
- Levodopa with carbidopa tab long-acting 100 mg with carbidopa 25 mg – new listing
- Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate (Klean Prep) powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – addition of HSS
- Magnesium amino acid chelate cap 750 mg (150 mg elemental) – new listing
- Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) – new listing

Summary of decisions – effective 1 May 2019 (continued)

- Metronidazole (Baxter) inj 5 mg per ml, 100 ml bag, 48 inj pack – new listing
- Metronidazole (Baxter) inj 5 mg per ml, 100 ml bag, 10 inj pack
– to be delisted from 1 November 2019
- Moroctocog alfa [recombinant factor VIII] (Xyntha) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu prefilled syringe – amended restriction criteria
- Nonacog alfa [recombinant factor IX] (BeneFIX) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vial – to be delisted from 1 November 2019
- Nonacog gamma [recombinant factor IX] (RIXUBIS) inj 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vial – price decrease and amended restriction criteria
- Nonacog gamma [recombinant factor IX] (RIXUBIS) inj 250 iu vial
– delisted 1 May 2019
- Octocog alfa [recombinant factor VIII] (Advate) inj 250 iu, 500 iu, 1,000 iu, 1,500 iu, 2,000 iu and 3,000 iu vial – price decrease and amended restriction criteria
- Octocog alfa [recombinant factor VIII] (Kogenate FS) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vial – amended restriction criteria
- Pizotifen (Sandomigran) tab 500 mcg – to be delisted from 1 November 2019
- Rurioctocog alfa pegol [recombinant factor VIII] (Adynovate) inj 250 iu, 500 iu, 1,000 iu and 2,000 iu vial – new listing

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 May 2019

ALIMENTARY TRACT AND METABOLISM

11	MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE (addition of HSS) Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – 1% DV Aug-19 to 2022	14.31	4	Klean Prep
18	MAGNESIUM AMINO ACID CHELATE (new listing) Cap 750 mg (150 mg elemental)			
18	MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE (new listing) Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)			

BLOOD AND BLOOD FORMING ORGANS

27	EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] (new listing) → Inj 250 iu vial → Inj 500 iu vial → Inj 1,000 iu vial → Inj 2,000 iu vial → Inj 3,000 iu vial	612.50 1,225.00 2,450.00 4,900.00 7,350.00	1 1 1 1 1	Alprolix Alprolix Alprolix Alprolix Alprolix
	Restricted Initiation For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treeters Group in conjunction with the National Haemophilia Management Group.			
27	EPTACOG ALFA [RECOMBINANT FACTOR VIIA] (amended restriction criteria) → Inj 1 mg syringe → Inj 2 mg syringe → Inj 5 mg syringe → Inj 8 mg syringe	1,178.30 2,356.60 5,891.50 9,426.40	1 1 1 1	NovoSeven RT NovoSeven RT NovoSeven RT NovoSeven RT
	Restricted Initiation When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treeters Group in conjunction with the National Haemophilia Management Group. For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treeters Group in conjunction with the National Haemophilia Management Group.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2019 (continued)

27	FACTOR EIGHT INHIBITOR BYPASSING FRACTION (↓ price and amended restriction criteria)		
	→ Inj 500 U.....	1,315.50	1 FEIBA NF
	→ Inj 1,000 U.....	2,630.00	1 FEIBA NF
	→ Inj 2,500 U.....	6,575.00	1 FEIBA NF
	Restricted Initiation		
	When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.		
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.		
28	MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] (amended restriction criteria)		
	→ Inj 250 iu prefilled syringe	210.00	1 Xyntha
	→ Inj 500 iu prefilled syringe	420.00	1 Xyntha
	→ Inj 1,000 iu prefilled syringe	840.00	1 Xyntha
	→ Inj 2,000 iu prefilled syringe	1,680.00	1 Xyntha
	→ Inj 3,000 iu prefilled syringe	2,520.00	1 Xyntha
	Restricted Initiation		
	Note: Preferred Brand of recombinant factor VIII from 1 March 2016. When used in the treatment of haemophilia, funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.		
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.		
28	NONACOG ALFA [RECOMBINANT FACTOR IX] (delisting)		
	→ Inj 250 iu vial	310.00	1 BeneFIX
	→ Inj 500 iu vial	620.00	1 BeneFIX
	→ Inj 1,000 iu vial	1,240.00	1 BeneFIX
	→ Inj 2,000 iu vial	2,480.00	1 BeneFIX
	→ Inj 3,000 iu vial	3,720.00	1 BeneFIX
	Note – BeneFIX inj 250 iu vial, 500 iu vial, 1,000 iu vial, 2,000 iu vial and 3,000 iu vial to be delisted from 1 November 2019.		
28	NONACOG GAMMA, [RECOMBINANT FACTOR IX] (↓ price and amended restriction criteria)		
	→ Inj 500 iu vial	435.00	1 RIXUBIS
	→ Inj 1,000 iu vial	870.00	1 RIXUBIS
	→ Inj 2,000 iu vial	1,740.00	1 RIXUBIS
	→ Inj 3,000 iu vial	2,610.00	1 RIXUBIS
	Restricted Initiation		
	When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.		
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.		
28	NONACOG GAMMA, [RECOMBINANT FACTOR IX] (delisted)		
	→ Inj 250 iu vial	287.50	1 RIXUBIS
	Note – RIXUBIS inj 250 iu vial delisted from 1 May 2019.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2019 (continued)

28	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) (↓ price and amended restriction criteria)		
	→ Inj 250 iu vial	210.00	1 Advate
	→ Inj 500 iu vial	420.00	1 Advate
	→ Inj 1,000 iu vial	840.00	1 Advate
	→ Inj 1,500 iu vial	1,260.00	1 Advate
	→ Inj 2,000 iu vial	1,680.00	1 Advate
	→ Inj 3,000 iu vial	2,520.00	1 Advate

Restricted

Initiation

Notes: Rare Clinical Circumstances Brand of recombinant factor VIII from 1 March 2016. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Haemophilia Treatments Panel

Phone: 0800 023 588 Option 2

PHARMAC PO Box 10-254

Facsimile: (04) 974 4881

Wellington

Email: haemophilia@pharmac.govt.nz

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

29	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) (amended restriction criteria)		
	→ Inj 250 iu vial	237.50	1 Kogenate FS
	→ Inj 500 iu vial	475.00	1 Kogenate FS
	→ Inj 1,000 iu vial	950.00	1 Kogenate FS
	→ Inj 2,000 iu vial	1,900.00	1 Kogenate FS
	→ Inj 3,000 iu vial	2,850.00	1 Kogenate FS

Restricted

Initiation

Notes: Second Brand of recombinant factor VIII from 1 March 2016. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Haemophilia Treatments Panel

Phone: 0800 023 588 Option 2

PHARMAC PO Box 10-254

Facsimile: (04) 974 4881

Wellington

Email: haemophilia@pharmac.govt.nz

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

29	RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] (new listing)		
	→ Inj 250 iu vial	300.00	1 Adynovate
	→ Inj 500 iu vial	600.00	1 Adynovate
	→ Inj 1,000 iu vial	1,200.00	1 Adynovate
	→ Inj 2,000 iu vial	2,400.00	1 Adynovate

Restricted

Initiation

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

INFECTIONS

72	ERTAPENEM (↓ price and addition of HSS)		
	→ Inj 1 g vial – 1% DV Aug-19 to 2022	70.00	1 Invanz

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2019 (continued)

78	DOXYCYCLINE (new pack size) Tab 100 mg	64.43	500	Doxine
78	DOXYCYCLINE (delisting) Tab 100 mg	6.75	250	Doxine
	Note – Doxine tab 100 mg, 250 tab pack to be delisted from 1 November 2019.			
84	METRONIDAZOLE (pack size change) Inj 5 mg per ml, 100 ml bag.....	264.00	48	Baxter
	Note – Baxter inj 5 mg per ml, 100 ml bag, 10 inj pack to be delisted from 1 November 2019.			

NERVOUS SYSTEM

104	LEVODOPA WITH CARBIDOPA (new listing) Tab long-acting 100 mg with carbidopa 25 mg			
105	BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE (↓ price and addition of HSS) Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Aug-19 to 2022	94.50	5	Marcaïn with Adrenaline
	Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Aug-19 to 2022	80.50	5	Marcaïn with Adrenaline
114	LAMOTRIGINE (↓ price and addition of HSS) Tab dispersible 25 mg – 5% DV Oct-19 to 2022	2.76	56	Logem
	Tab dispersible 50 mg – 5% DV Oct-19 to 2022	3.31	56	Logem
	Tab dispersible 100 mg – 5% DV Oct-19 to 2022	4.40	56	Logem
114	LAMOTRIGINE (delisting) Tab dispersible 25 mg	20.40	56	Arrow-Lamotrigine Lamictal
	Tab dispersible 50 mg	29.09		
	Tab dispersible 100 mg	34.70	56	Arrow-Lamotrigine Lamictal
	Tab dispersible 25 mg	47.89		
	Tab dispersible 50 mg	59.90	56	Arrow-Lamotrigine Lamictal
	Tab dispersible 100 mg	79.16		
	Note – Arrow-Lamotrigine and Lamictal tab dispersible 25 mg, 50 mg and 100 mg to be delisted from 1 October 2019.			
114	LEVETIRACETAM (↓ price and addition of HSS) Tab 250 mg – 1% DV Aug-19 to 2022	4.99	60	Everet
	Tab 500 mg – 1% DV Aug-19 to 2022	8.79	60	Everet
	Tab 750 mg – 1% DV Aug-19 to 2022	14.39	60	Everet
	Tab 1,000 mg – 1% DV Aug-19 to 2022	18.59	60	Everet
116	PIZOTIFEN (delisting) Tab 500 mcg.....	23.21	100	Sandomigran
	Note – Sandomigran tab 500 mcg (Pharmacode 251666) to be delisted from 1 November 2019.			

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 May 2019 (continued)

VARIOUS

- 202 FLUMAZENIL (pack size change)
 Inj 0.1 mg per ml, 5 ml ampoule – **1% DV Dec-18 to 2021** 132.68 10 **Hameln**
 Note – Hameln inj 0.1 mg per ml, 5 ml ampoule, 5 inj pack to be delisted from 1 August 2019.
- 207 CHLORHEXIDINE WITH CETRIMIDE (new listing)
 → Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle
 Restricted
 Initiation
 Re-assessment required after 3 months
 All of the following:
 1 Patient has burns that are greater than 30% of total body surface area (BSA); and
 2 For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting;
 and
 3 The use of 30 ml ampoules is impractical due to the size of the area to be covered.
 Continuation
 Re-assessment required after 3 months
 The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

- 209 COMPOUND HYDROXYBENZOATE (new listing)
 Soln – **1% DV Aug-19 to 2022** 30.00 100 ml **Midwest**

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2019

ALIMENTARY TRACT AND METABOLISM

17	CALCIUM CARBONATE (delisting delayed) Tab eff 1.75 g (1 g elemental).....	2.07	10	Calsource
	Note – Calsource tab eff 1.75 g (1 g elemental) delisting delayed from 1 July 2019 to 1 September 2019.			

CARDIOVASCULAR SYSTEM

39	AMIODARONE HYDROCHLORIDE (HSS suspended) Inj 50 mg per ml, 3 ml ampoule – 1% DV Jun-17 to 2019 31 March 2019	9.98	5	Lodi
39	AMIODARONE HYDROCHLORIDE (new listing) Inj 50 mg per ml, 3 ml ampoule.....	11.98	6	Cordarone-X

DERMATOLOGICALS

54	HYDROCORTISONE BUTYRATE (1 price) Crm 0.1%.....	3.42	30 g	Locoid Lipocream
----	--	------	------	------------------

INFECTIONS

72	IMIPENEM WITH CILASTATIN (addition of HSS) → Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022	60.00	1	Imipenem + Cilastatin RBX
86	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (new listing) → Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – 1% DV Jun-19 to 2022 ..	106.88	30	Mylan
86	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (amended chemical and presentation name and delisting) → Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate).....	237.52	30	Atripla
	Note – Atripla to be delisted from 1 June 2019.			
87	ATAZANAVIR SULPHATE (brand change) → Cap 150 mg – 1% DV Jun-19 to 2022	141.68	60	Teva
	→ Cap 200 mg – 1% DV Jun-19 to 2022	188.91	60	Teva
	Note – Reyataz cap 150 mg and 200 mg to be delisted from 1 June 2019.			
90	EMTRICITABINE WITH TENOFOVIR DISOPROXIL (new listing) → Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – 1% DV Jun-19 to 2022	61.15	30	Teva

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

Changes to Section H Part II – effective 1 April 2019 (continued)

90	EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE (amended chemical and presentation name and delisting) → Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate).....	190.02	30	Truvada
	Note – Truvada to be delisted from 1 June 2019.			

NERVOUS SYSTEM

109	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (addition of HSS) Spray 10% – 1% DV Jul-19 to 2022	75.00	50 ml	Xylocaine
109	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↓ price and addition of HSS) Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022	6.20	5	Lidocaine-Claris
	Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022	6.45	5	Lidocaine-Claris
109	PRILOCAINE HYDROCHLORIDE (delisting) Inj 2%, 5 ml ampoule.....	55.00	10	Citanest
	Note – Citanest inj 2%, 5 ml ampoule to be delisted from 1 October 2019.			
119	METOCLOPRAMIDE HYDROCHLORIDE (↑ price) Inj 5 mg per ml, 2 ml ampoule	13.56	10	Pfizer

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

133	MERCAPTOPURINE (↓ price and addition of HSS) Tab 50 mg – 1% DV Jul-19 to 2022	37.00	25	Puri-nethol
135	ETOPOSIDE (addition of HSS) Cap 50 mg – 1% DV Jul-19 to 2022	340.73	20	Vepesid
	Cap 100 mg – 1% DV Jul-19 to 2022	340.73	10	Vepesid
138	CARBOPLATIN (brand change) Inj 10 mg per ml, 45 ml vial – 1% DV Jun-19 to 2021	45.20	1	Carboplatin Ebewe
	Note – DBL Carboplatin inj 10 mg per ml, 45 ml vial to be delisted from 1 June 2019.			

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

212	GLYCERIN WITH SODIUM SACCHARIN (↓ price and addition of HSS) Suspension – 1% DV Jul-19 to 2022	30.95	473 ml	Ora-Sweet SF
212	GLYCERIN WITH SUCROSE (↓ price and addition of HSS) Suspension – 1% DV Jul-19 to 2022	30.95	473 ml	Ora-Sweet
212	METHYL HYDROXYBENZOATE (new listing) Powder – 1% DV Jul-19 to 2022	8.98	25 g	Midwest
212	METHYLCELLULOSE (new listing) Powder – 1% DV Jul-19 to 2022	36.95	100 g	Midwest

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2019 (continued)

212	METHYLCELLULOSE (↓ price and addition of HSS) Suspension – 1% DV Jul-19 to 2022.....	30.95	473 ml	Ora-Plus
212	METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN (↓ price and addition of HSS) Suspension – 1% DV Jul-19 to 2022.....	30.95	473 ml	Ora-Blend SF
212	METHYLCELLULOSE WITH GLYCERIN AND SUCROSE (↓ price and addition of HSS) Suspension – 1% DV Jul-19 to 2022.....	30.95	473 ml	Ora-Blend

VACCINES

235	INFLUENZA VACCINE (Pharmacode change) → Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).....	90.00	10	Influvac Tetra Note – this is a new Pharmacode listing, 2558483. Pharmacode 2538466 to be delisted from 1 July 2019.			
235	INFLUENZA VACCINE (amended restriction – affected criteria only shown) → Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) ..	9.00	1	Fluarix Tetra Restricted Initiation – Other conditions for patients aged 6 months to 35 months Any of the following: 1 Any of the following: 1.1 Diabetes; or 1.2 Chronic renal disease; or 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or 1.4 Autoimmune disease; or 1.5 Immune suppression or immune deficiency; or 1.6 HIV; or 1.7 Transplant recipient; or 1.8 Neuromuscular and CNS diseases/ disorders; or 1.9 Haemoglobinopathies; or 1.10 Is a child on long term aspirin; or 1.11 Has a cochlear implant; or 1.12 Errors of metabolism at risk of major metabolic decompensation; or 1.13 Pre and post splenectomy; or 1.14 Down syndrome; or 1.15 Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or 2 Child is living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board) → Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).....	90.00	10	Influvac Tetra Initiation – Other conditions for patients 3 years and over Any of the following: Either: 1 Any of the following: 1.1 Diabetes; or 1.2 chronic renal disease; or 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or 1.4 Autoimmune disease; or 1.5 Immune suppression or immune deficiency; or 1.6 HIV; or 1.7 Transplant recipient; or 1.8 Neuromuscular and CNS diseases/ disorders; or

continued...

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 April 2019 (continued)

continued...

- 1.9 Haemoglobinopathies; or
- 1.10 Is a child on long term aspirin; or
- 1.11 Has a cochlear implant; or
- 1.12 Errors of metabolism at risk of major metabolic decompensation; or
- 1.13 Pre and post splenectomy; or
- 1.14 Down syndrome; or
- 1.15 Is pregnant; or
- 1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital; or
- ~~3 People under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board)~~

Index

Pharmaceuticals and brands

A	
Advate	7
Adynovate.....	7
Alprolix	5
Amiodarone hydrochloride.....	10
Arrow-Lamotrigine	8
Atazanavir sulphate	10
Atripla.....	10
B	
BeneFIX	6
Bupivacaine hydrochloride with adrenaline.....	8
C	
Calcium carbonate	10
Calsource	10
Carboplatin	11
Carboplatin Ebewe	11
Chlorhexidine with cetrimide.....	9
Citanest	11
Compound hydroxybenzoate	9
Cordarone-X	10
D	
Doxine	8
Doxycycline	8
E	
Efavirenz with emtricitabine and tenofovir disoproxil.....	10
Efavirenz with emtricitabine and tenofovir disoproxil fumarate	10
Eftrenonacog alfa [Recombinant factor IX].....	5
Emtricitabine with tenofovir disoproxil.....	10, 11
Emtricitabine with tenofovir disoproxil fumarate ..	11
Eptacog alfa [Recombinant factor VIIa]	5
Ertapenem	7
Etoposide.....	11
Everet	8
F	
Factor eight inhibitor bypassing fraction.....	6
FEIBA NF.....	6
Fluarix Tetra.....	12
Flumazenil.....	9
G	
Glycerin with sodium saccharin.....	11
Glycerin with sucrose.....	11
H	
Hydrocortisone butyrate.....	10
I	
Imipenem+ Cilastatin RBX.....	10
Imipenem with cilastatin	10
Influenza vaccine.....	12
Influvac Tetra	12
Invanz.....	7
K	
Klean Prep	5
Kogenate FS.....	7
L	
Lamictal.....	8
Lamotrigine.....	8
Levetiracetam	8
Levodopa with carbidopa	8
Lidocaine-Clarix	11
Lidocaine [Lignocaine] hydrochloride	11
Lignocaine	11
Locoid Lipocream	10
Lodi.....	10
Logem.....	8
M	
Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate.....	5
Magnesium amino acid chelate	5
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate.....	5
Marcain with Adrenaline.....	8
Mercaptopurine.....	11
Methylcellulose	11, 12
Methylcellulose with glycerin and sodium saccharin.....	12
Methylcellulose with glycerin and sucrose	12
Methyl hydroxybenzoate.....	11
Metoclopramide hydrochloride	11
Metronidazole	8
Morococog alfa [Recombinant factor VIII].....	6
N	
Nonacog alfa [Recombinant factor IX]	6
Nonacog gamma, [Recombinant factor IX]	6
NovoSeven RT	5
O	
Octocog alfa [Recombinant factor VIII] (Advate) ...	7
Octocog alfa [Recombinant factor VIII] (Kogenate FS)	7
Ora-Blend	12
Ora-Blend SF.....	12
Ora-Plus	12
Ora-Sweet.....	11
Ora-Sweet SF.....	11
P	
Pizotifen.....	8
Prilocaine hydrochloride.....	11
Puri-nethol	11

Index

Pharmaceuticals and brands

R

Recombinant factor IX.....	5, 6
Recombinant factor VIIa	5
Recombinant factor VIII.....	6, 7
RIXUBIS	6
Rurioctocog alfa pegol [Recombinant factor VIII] ..	7

S

Sandomigran	8
-------------------	---

T

Truvada	11
---------------	----

V

Vepesid.....	11
--------------	----

X

Xylocaine	11
-----------------	----

Xyntha	6
--------------	---



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990

Fax: 64 4 460 4995

Website: www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3694 (Print)

ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand